Literature DB >> 11238151

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial.

U Eriksson1, B Seifert, A Schaffner.   

Abstract

OBJECTIVE: To test the hypothesis that amphotericin B deoxycholate is less toxic when given by continuous infusion than by conventional rapid infusion.
DESIGN: Randomised, controlled, non-blinded, single centre study.
SETTING: University hospital providing tertiary clinical care. PATIENTS: 80 mostly neutropenic patients with refractory fever and suspected or proved invasive fungal infections. INTERVENTION: Patients were randomised to receive 0.97 mg/kg amphotericin B by continuous infusion over 24 hours or 0.95 mg/kg by rapid infusion over four hours. MAIN OUTCOME MEASURES: Patients were evaluated for side effects related to infusion, nephrotoxicity, and mortality up to three months after treatment. Analysis was on an intention to treat basis.
RESULTS: Patients in the continuous infusion group had fewer side effects and significantly reduced nephrotoxicity than those in the rapid infusion group. Overall mortality was higher during treatment and after three months' follow up in the rapid infusion than in the continuous infusion group.
CONCLUSION: Continuous infusions of amphotericin B reduce nephrotoxicity and side effects related to infusion without increasing mortality.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238151      PMCID: PMC26549          DOI: 10.1136/bmj.322.7286.579

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  22 in total

1.  Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations.

Authors:  E C Oldfield; P D Garst; C Hostettler; M White; D Samuelson
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B.

Authors:  M E Ellis; A A al-Hokail; H M Clink; M A Padmos; P Ernst; D G Spence; W N Tharpe; V F Hillier
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

4.  Estimation of a common effect parameter from sparse follow-up data.

Authors:  S Greenland; J M Robins
Journal:  Biometrics       Date:  1985-03       Impact factor: 2.571

5.  Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure.

Authors:  M Arning; R E Scharf
Journal:  Klin Wochenschr       Date:  1989-10-17

Review 6.  AmBisome targeting to fungal infections.

Authors:  J Adler-Moore
Journal:  Bone Marrow Transplant       Date:  1994       Impact factor: 5.483

7.  Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients.

Authors:  G G Chabot; R Pazdur; F A Valeriote; L H Baker
Journal:  J Pharm Sci       Date:  1989-04       Impact factor: 3.534

8.  Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients.

Authors:  W Mills; R Chopra; D C Linch; A H Goldstone
Journal:  Br J Haematol       Date:  1994-04       Impact factor: 6.998

9.  Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells.

Authors:  J D Cleary; S W Chapman; R L Nolan
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  Rapid intravenous infusion of amphotericin B: a pilot study.

Authors:  J M Cruz; J E Peacock; L Loomer; L W Holder; G W Evans; B L Powell; E S Lyerly; R L Capizzi
Journal:  Am J Med       Date:  1992-08       Impact factor: 4.965

View more
  31 in total

Review 1.  [New medications for treatment of systemic mycoses].

Authors:  I Schedel
Journal:  Internist (Berl)       Date:  2005-06       Impact factor: 0.743

Review 2.  Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters.

Authors:  Sofia K Kasiakou; Kenneth R Lawrence; Nicolaos Choulis; Matthew E Falagas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

4.  Encapsulation and release of Amphotericin B from an ABC triblock fluorous copolymer.

Authors:  Jun-Pil Jee; Aaron McCoy; Sandro Mecozzi
Journal:  Pharm Res       Date:  2011-07-08       Impact factor: 4.200

Review 5.  Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia.

Authors:  Helle Krogh Johansen; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2014-09-04

Review 6.  Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.

Authors:  Helle Krogh Johansen; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2014-09-04

7.  New automated method for determining postantifungal effect of amphotericin B against Candida species: effects of concentration, exposure time, and area under the curve.

Authors:  Erja Chryssanthou; Otto Cars; Jan Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 8.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

9.  Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations.

Authors:  Eden C Andrew; Nigel Curtis; Ben Coghlan; Noel Cranswick; Amanda Gwee
Journal:  Br J Clin Pharmacol       Date:  2018-03-01       Impact factor: 4.335

10.  Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors:  Rafael Zaragoza; Javier Pemán; Miguel Salavert; Angel Viudes; Amparo Solé; Isidro Jarque; Emilio Monte; Eva Romá; Emilia Cantón
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.